GW Pharmaceuticals PLC Company Profile (NASDAQ:GWPH)

About GW Pharmaceuticals PLC (NASDAQ:GWPH)

GW Pharmaceuticals PLC logoGW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GWPH
  • CUSIP: N/A
  • Web: www.gwpharm.com
Capitalization:
  • Market Cap: $2.9586 billion
  • Outstanding Shares: 25,308,000
Average Prices:
  • 50 Day Moving Avg: $104.85
  • 200 Day Moving Avg: $114.17
  • 52 Week Range: $79.62 - $137.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -24.37
  • P/E Growth: 0.45
Sales & Book Value:
  • Annual Revenue: $10.07 million
  • Price / Sales: 294.57
  • Book Value: $18.35 per share
  • Price / Book: 6.39
Profitability:
  • EBIDTA: ($159,690,000.00)
  • Net Margins: -1,021.38%
  • Return on Equity: -22.81%
  • Return on Assets: -19.68%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 13.46%
  • Quick Ratio: 13.28%
Misc:
  • Average Volume: 272,508 shs.
  • Beta: 2.66
  • Short Ratio: 10.14
 
Frequently Asked Questions for GW Pharmaceuticals PLC (NASDAQ:GWPH)

What is GW Pharmaceuticals PLC's stock symbol?

GW Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC's earnings last quarter?

GW Pharmaceuticals PLC (NASDAQ:GWPH) announced its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.50) by $0.20. The company had revenue of $2.04 million for the quarter, compared to analysts' expectations of $2.07 million. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The company's revenue was down 23.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.06) earnings per share. View GW Pharmaceuticals PLC's Earnings History.

When will GW Pharmaceuticals PLC make its next earnings announcement?

GW Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for GW Pharmaceuticals PLC.

Where is GW Pharmaceuticals PLC's stock going? Where will GW Pharmaceuticals PLC's stock price be in 2017?

8 brokerages have issued 1-year price targets for GW Pharmaceuticals PLC's stock. Their forecasts range from $135.00 to $208.00. On average, they expect GW Pharmaceuticals PLC's stock price to reach $161.71 in the next year. View Analyst Ratings for GW Pharmaceuticals PLC.

What are analysts saying about GW Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC stock:

  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (7/24/2017)
  • 2. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)
  • 3. Cantor Fitzgerald analysts commented, "NDA Filing Expected Mid-2017. GWPH expects to complete its filing in the U.S. shortly and noted two key portions in progress: 1) an integrated safety analysis of over 1,500 treated patients from clinical studies and the expanded access program, and 2) manufacturing data from the company’s manufacturing processes, including scaled materials. These elements will be the two determining factors of the timing of the NDA submission, which is expected in the middle of the year. Following the U.S. submission, GW expects to submit its MAA filing in 2H17 and plans to meet with the EMA in the near term. Pre-commercialization Activities Intensify. Greenwich Biosciences, the U.S. subsidiary of GW, is progressing with a pre-commercial strategy of expanding its team for the drug launch of Epidiolex. GW guided for a commercial team consisting of 15 medical-science liaisons by the end of 2017 and a sales force of 50-60 sales representatives to reach 4,000-5,000 targeted U.S. physicians. In addition, the company has begun to engage payors on awareness of patient need, Epidiolex, and pricing. We believe these efforts will set a meaningful foundation for Epidiolex’s commercial launch, which we estimate will initiate in 2018. Model Update. Following F2Q17 financial results, we have updated our model to reflect recent quarterly results and future expectations of operational expenditures." (5/9/2017)

Who are some of GW Pharmaceuticals PLC's key competitors?

Who are GW Pharmaceuticals PLC's key executives?

GW Pharmaceuticals PLC's management team includes the folowing people:

  • Geoffrey W. Guy, Executive Chairman of the Board
  • Justin Gover, Chief Executive Officer, Director
  • Adam David George, Chief Financial Officer, Company Secretary, Director
  • Christopher John Tovey, Chief Operating Officer, Executive Director
  • Julian S. Gangolli, Executive Director
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
  • Cabot Brown, Non-Executive Independent Director
  • Thomas Gerard Lynch, Non-Executive Independent Director

Who owns GW Pharmaceuticals PLC stock?

GW Pharmaceuticals PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Greenleaf Trust (0.31%), ING Groep NV (0.08%), Rothschild Investment Corp IL (0.08%), US Bancorp DE (0.05%), Woodstock Corp (0.02%) and Fox Run Management L.L.C. (0.02%). View Institutional Ownership Trends for GW Pharmaceuticals PLC.

Who sold GW Pharmaceuticals PLC stock? Who is selling GW Pharmaceuticals PLC stock?

GW Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Profit Investment Management LLC, Greenleaf Trust, Bank of Montreal Can and US Bancorp DE. View Insider Buying and Selling for GW Pharmaceuticals PLC.

Who bought GW Pharmaceuticals PLC stock? Who is buying GW Pharmaceuticals PLC stock?

GW Pharmaceuticals PLC's stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, Fox Run Management L.L.C., Quantitative Systematic Strategies LLC, Aperio Group LLC, ING Groep NV, Eqis Capital Management Inc. and Creative Planning. View Insider Buying and Selling for GW Pharmaceuticals PLC.

How do I buy GW Pharmaceuticals PLC stock?

Shares of GW Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GW Pharmaceuticals PLC's stock price today?

One share of GW Pharmaceuticals PLC stock can currently be purchased for approximately $117.21.


MarketBeat Community Rating for GW Pharmaceuticals PLC (NASDAQ GWPH)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GW Pharmaceuticals PLC (NASDAQ:GWPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $161.71 (37.97% upside)

Analysts' Ratings History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Maxim GroupSet Price TargetBuy$135.00HighView Rating Details
5/9/2017Cantor FitzgeraldReiterated RatingBuy$208.00HighView Rating Details
2/22/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$185.00N/AView Rating Details
2/6/2017Cowen and CompanySet Price TargetBuy$135.00N/AView Rating Details
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$162.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 -> $160.00N/AView Rating Details
8/26/2016Numis Securities LtdUpgradeSell -> HoldN/AView Rating Details
7/18/2016Bank of America CorporationReiterated RatingBuy$153.00N/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
3/14/2016Roth CapitalBoost Price TargetBuy$130.00 -> $160.00N/AView Rating Details
(Data available from 7/29/2015 forward)

Earnings

Earnings History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Earnings History by Quarter for GW Pharmaceuticals PLC (NASDAQ GWPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017($1.73)N/AView Earnings Details
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)ViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GW Pharmaceuticals PLC (NASDAQ:GWPH)
2017 EPS Consensus Estimate: ($8.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.80)($1.80)($1.80)
Q2 20171($1.98)($1.98)($1.98)
Q3 20172($2.34)($2.18)($2.26)
Q4 20171($2.49)($2.49)($2.49)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for GW Pharmaceuticals PLC (NASDAQ:GWPH)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Latest Headlines for GW Pharmaceuticals PLC (NASDAQ:GWPH)
Source:
DateHeadline
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 29 at 12:43 AM
finance.yahoo.com logoMassRoots (MSRT), the Yelp of Cannabis, Moves into Point of Sale Solutions for Dispensaries
finance.yahoo.com - July 25 at 7:34 PM
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 25 at 12:52 AM
nasdaq.com logoGW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017 - Nasdaq
www.nasdaq.com - July 24 at 9:46 PM
finance.yahoo.com logoGW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017
finance.yahoo.com - July 24 at 9:46 PM
finance.yahoo.com logo10 Stocks to Give as Gifts
finance.yahoo.com - July 24 at 9:46 PM
finance.yahoo.com logoIt Took Just 10 Days for Nevada's Recreational Marijuana Industry to Fall Into a State of Emergency
finance.yahoo.com - July 22 at 7:45 PM
americanbankingnews.com logoZacks Investment Research Upgrades GW Pharmaceuticals PLC- (GWPH) to "Buy"
www.americanbankingnews.com - July 17 at 11:08 PM
americanbankingnews.com logo Brokerages Anticipate GW Pharmaceuticals PLC (NASDAQ:GWPH) Will Post Quarterly Sales of $2.84 Million
www.americanbankingnews.com - July 15 at 8:36 AM
finance.yahoo.com logo5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals
finance.yahoo.com - July 14 at 8:31 PM
americanbankingnews.com logo Brokerages Anticipate GW Pharmaceuticals PLC (NASDAQ:GWPH) Will Post Earnings of -$1.73 Per Share
www.americanbankingnews.com - July 13 at 12:27 PM
bloomberg.com logoOne FDA About-Face Doesn't Mean an Orphan-Drug Bonanza
www.bloomberg.com - July 13 at 1:06 AM
investorplace.com logoGet Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free - Investorplace.com
investorplace.com - July 12 at 8:02 PM
investorplace.com logoGet Long GW Pharmaceuticals PLC- ADR (GWPH) Stock for Free
investorplace.com - July 12 at 12:33 PM
seekingalpha.com logoGW Pullback Is A Buy - Seeking Alpha
seekingalpha.com - July 11 at 8:50 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW Pharmaceuticals
finance.yahoo.com - July 11 at 8:50 PM
finance.yahoo.com logoPuration Announces $1.2 Million Sales Contract Adding to Existing Cannabis Extraction Business With Expansion Potential to $16 Million Annually
finance.yahoo.com - July 11 at 8:50 PM
americanbankingnews.com logoZacks Investment Research Downgrades GW Pharmaceuticals PLC (GWPH) to Sell
www.americanbankingnews.com - July 9 at 2:56 PM
seekingalpha.com logoPolitical Risk Increases For Medical Marijuana - Seeking Alpha
seekingalpha.com - July 4 at 4:59 AM
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 12:32 AM
finance.yahoo.com logo3 Marijuana Stocks to Buy If You've Never Bought a Marijuana Stock
finance.yahoo.com - June 25 at 6:14 PM
finance.yahoo.com logoSurprise! Jeff Sessions Wants to Trample States' Rights and Prosecute Medical Marijuana Businesses
finance.yahoo.com - June 24 at 5:55 PM
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - June 21 at 10:38 PM
finance.yahoo.com logoBiotech Industry Showing Signs of a Revival in 2017: Today's Research on GW Pharmaceuticals and ZIOPHARM Oncology
finance.yahoo.com - June 21 at 7:16 PM
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - June 21 at 6:56 PM
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Expected to Post Quarterly Sales of $2.84 Million
www.americanbankingnews.com - June 21 at 10:44 AM
americanbankingnews.com logoZacks: Analysts Expect GW Pharmaceuticals PLC (GWPH) to Announce -$1.73 Earnings Per Share
www.americanbankingnews.com - June 19 at 12:48 PM
finance.yahoo.com logo5 Critical Questions for One of the Biggest Marijuana Stocks on the Market
finance.yahoo.com - June 16 at 6:22 PM
seekingalpha.com logoMedical Marijuana Investing Recommendations - Seeking Alpha
seekingalpha.com - June 16 at 12:52 AM
finance.yahoo.com logoCannabis Is Todd Hagopian's Top Biotech Sub-Sector
finance.yahoo.com - June 15 at 7:50 PM
americanbankingnews.com logoGW Pharmaceuticals PLC (GWPH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - June 14 at 8:28 PM
finance.yahoo.com logoWill Donald Trump's Attorney General Jeff Sessions Undermine Legal Marijuana?
finance.yahoo.com - June 14 at 7:09 PM
americanbankingnews.com logoMaxim Group Analysts Give GW Pharmaceuticals PLC- (GWPH) a $135.00 Price Target
www.americanbankingnews.com - June 11 at 8:30 AM
finance.yahoo.com logoHow Big Is the Marijuana Stock Opportunity in Cannabidiol?
finance.yahoo.com - June 10 at 5:36 PM
finance.yahoo.com logoThis Marijuana Stock Darling Crashed 17% in May
finance.yahoo.com - June 8 at 6:35 PM
nasdaq.com logoGW Pharmaceuticals to Present at the Goldman Sachs 38th Annual ... - Nasdaq
www.nasdaq.com - June 7 at 5:07 PM
americanbankingnews.com logoGW Pharmaceuticals PLC- (GWPH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 7 at 12:44 AM
finance.yahoo.com logoZogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
finance.yahoo.com - June 5 at 5:43 PM
finance.yahoo.com logoWhich Marijuana Stock Could Be First to $1 Billion in Annual Sales?
finance.yahoo.com - June 5 at 10:45 AM
finance.yahoo.com logoMarijuana Stock Investors Are Denied! Vermont's Governor Vetoes Recreational Marijuana Bill
finance.yahoo.com - June 3 at 5:21 PM
bizjournals.com logoSchizophrenia Pipeline Therapeutics Development, Drug Profiles and Key Players Market Analysis Report Now Available at RnRMarketResearch.com
www.bizjournals.com - May 31 at 10:35 PM
nasdaq.com logoGW Pharmaceuticals is Now Oversold (GWPH) - Nasdaq
www.nasdaq.com - May 31 at 5:33 PM
finance.yahoo.com logoMarijuana News Roundup: Medical Marijuana Could Cost Big Pharma $4 Billion
finance.yahoo.com - May 28 at 6:05 PM
finance.yahoo.com logoETFs with exposure to GW Pharmaceuticals Plc : May 26, 2017
finance.yahoo.com - May 27 at 5:57 PM
americanbankingnews.com logoGW Pharmaceuticals PLC- (GWPH) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - May 25 at 1:21 PM
nasdaq.com logoAERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI
www.nasdaq.com - May 25 at 3:28 AM
finance.yahoo.com logoCannabis Drug Halved Convulsions in Company-Funded Epilepsy Test
finance.yahoo.com - May 25 at 3:28 AM
streetinsider.com logoGW Pharma (GWPH) Announces Publication of Epidiolex Study in NEJM - StreetInsider.com
www.streetinsider.com - May 24 at 5:26 PM
finance.yahoo.com logoGW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex® (cannabidiol) in The New England Journal of Medicine
finance.yahoo.com - May 24 at 5:26 PM
seekingalpha.com logoGW Pharmaceuticals - Cannabis Cannabinoid - Seeking Alpha
seekingalpha.com - May 21 at 8:17 AM

Social

Chart

GW Pharmaceuticals PLC (GWPH) Chart for Saturday, July, 29, 2017

This page was last updated on 7/29/2017 by MarketBeat.com Staff